Research Study Investigating How Well Semaglutide Works in People From Thailand and South Korea Living With Obesity
NCT04998136 · Completed
Last updated 2026-05-28This clinical trial is testing how well the medication semaglutide reduces body weight in adults from Thailand and South Korea who are living with obesity.
What this study is testing ClinicalTrials.gov NCT04998136 ↗
Description as written by the study sponsor.
This study looks at how well semaglutide helps people lose weight. This study will look at the change in the participants' body weight from the start to the end of the study. The study compares the weight loss in people who get semaglutide to the weight loss in people who get placebo. Placebo is a "dummy" medicine that looks like the study medicine, but has no effect on the body. Participants will either get semaglutide or "dummy" medicine - which treatment participants get is decided by chance. Participants will need to take 1 injection once a week. The study medicine is injected with a thin needle in a skin fold in the stomach, thigh or upper arm. Participants will also have talks with study staff about healthy food choices, how to be more physically active and what participants can do to lose weight. The study will last for about a year (50 weeks). Participants will have 10 clinic visits and 8 phone calls. At 6 of the clinic visits participants will have blood samples taken. Participants cannot take part if participants have or have had diabetes. Women cannot take part if pregnant, breast-feeding or plan to get pregnant during the study period.
Treatments tested
- Semaglutide 2.4 mg Drug
Administered subcutaneously (s.c., under the skin) as well as reduced-calorie diet and increased physical activity for 44 weeks. Doses gradually increased to 2.4 mg
- Placebo (semaglutide 2.4 mg) Drug
Administered s.c. as well as reduced-calorie diet and increased physical activity for 44 weeks
| Main thing measured | Change in Body Weight (%) : In-trial Observation Period |
|---|---|
| Sponsor | Novo Nordisk A/S |
| Conditions studied | Obesity |
| GLP-1 drugs | semaglutide |
Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT04998136 ↗